Literature DB >> 32390067

Calculating and Interpreting ICERs and Net Benefit.

Mike Paulden1.   

Abstract

For several decades, the incremental cost-effectiveness ratio has been routinely used by health technology assessment agencies around the world to summarise the results of economic evaluations of health interventions. Yet reporting and considering incremental cost-effectiveness ratios is unnecessary. Alternative summary measures exist, based on the concept of 'net benefit'. The incremental cost-effectiveness ratio and measures of net benefit share several commonalities but some important distinctions. As a result, different methods are required to calculate and interpret incremental cost-effectiveness ratios compared to measures of net benefit. The aim of this practical application is to introduce readers to these methods, using a hypothetical example to illustrate key issues. First, the methods used to calculate each measure are described. Next, for each measure, consideration is made of whether and how each measure may be interpreted to perform the following tasks, each of which may be of interest to health technology assessment agencies: (1) identifying the single most cost-effective strategy; (2) ranking strategies from 'most' to 'least' cost-effective (on an ordinal scale); (3) determining the magnitude to which a strategy is more or less cost-effective than another strategy (on a cardinal scale); and (4) determining whether a strategy is more or less cost-effective following a sensitivity or scenario analysis. This practical application also introduces a novel approach for visually interpreting measures of net benefit using the cost-effectiveness plane, which addresses a number of limitations of the conventional cost-effectiveness 'efficiency frontier'. By the end of this practical application, readers should have an understanding of how to calculate and interpret each measure, as well as the relative strengths and limitations of each.

Mesh:

Year:  2020        PMID: 32390067     DOI: 10.1007/s40273-020-00914-6

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

1.  Methodological Note: Reporting Deterministic versus Probabilistic Results of Markov, Partitioned Survival and Other Non-Linear Models.

Authors:  Edward C F Wilson
Journal:  Appl Health Econ Health Policy       Date:  2021-07-14       Impact factor: 2.561

2.  Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.

Authors:  Sabina Sanghera; Richard M Martin; Emma L Turner; Howard Thom; Edna Keeney; Roman Gulati; Fredrik Wiklund; Eleanor I Walsh; Jenny L Donovan; Freddie Hamdy; David E Neal; J Athene Lane; Mark S Clements
Journal:  Pharmacoeconomics       Date:  2022-10-06       Impact factor: 4.558

3.  HIV Rapid Testing in the General Population and the Usefulness of PrEP in Ecuador: A Cost-Utility Analysis.

Authors:  Paulina Quirola-Amores; Pablo Espinosa; Sebastian Oleas; Isabel Hernandez; Aquiles R Henriquez; Enrique Teran
Journal:  Front Public Health       Date:  2022-06-17

4.  Supporting a review of the benefits package of the National Health Insurance Scheme in Ghana.

Authors:  Heleen Vellekoop; Emmanuel Odame; Jessica Ochalek
Journal:  Cost Eff Resour Alloc       Date:  2022-07-16

5.  Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier.

Authors:  Christopher McCabe; Giovanni Tramonti; Andrew Sutton; Peter Hall; Mike Paulden
Journal:  Pharmacoeconomics       Date:  2020-11-23       Impact factor: 4.981

6.  The Application and Implications of Novel Deterministic Sensitivity Analysis Methods.

Authors:  Rick A Vreman; Joost W Geenen; Saskia Knies; Aukje K Mantel-Teeuwisse; Hubert G M Leufkens; Wim G Goettsch
Journal:  Pharmacoeconomics       Date:  2020-12-14       Impact factor: 4.981

Review 7.  Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization.

Authors:  Richard F Pollock; Fabien Colaone; Suki Shergill; Victoria K Brennan; Ion Agirrezabal
Journal:  Clinicoecon Outcomes Res       Date:  2021-09-22

8.  Cost-Effectiveness Analysis of CCTA in SUS, as Compared to Other Non-Invasive Imaging Modalities in Suspected Obstructive CAD.

Authors:  Patricia Bastos do Carmo; Carlos Alberto da Silva Magliano; Helena Cramer Veiga Rey; Gabriel C Camargo; Luís Filipe Lannes Trocado; Ilan Gottlieb
Journal:  Arq Bras Cardiol       Date:  2022-03       Impact factor: 2.000

9.  Short Term Economic Evaluation of the Digital Platform "Support, Monitoring and Reminder Technology for Mild Dementia" (SMART4MD) for People with Mild Cognitive Impairment and their Informal Caregivers.

Authors:  Zartashia Ghani; Sanjib Saha; Johan Jarl; Martin Andersson; Johan Sanmartin Berglund; Peter Anderberg
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

10.  Cost-effectiveness of hydroxychloroquine versus placebo for hand osteoarthritis: economic evaluation of the HERO trial.

Authors:  Sarah J Ronaldson; Ada Keding; Puvan Tharmanathan; Catherine Arundel; Sarah R Kingsbury; Philip G Conaghan; David J Torgerson
Journal:  F1000Res       Date:  2021-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.